01541.HK
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 3.40
+0.29%Aug 27, 2026, 13:21 UTC
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that the first patient has been dosed in its Phase II clinical trial of IMM2510 combined with IMM27M for first-line treatment of advanced hepatocellular carcinoma.
Aug 26, 2026, 18:39 UTC
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced its interim results for the six months ended June 30, with revenue of 25.42 million RMB, down 33.1% year-on-year, net loss widening to 164 million RMB, loss per share of 0.38 RMB, and no dividend.
Source:Aug 23, 2026, 10:44 UTC
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced that its investigational new drug application for IMM0306 for the treatment of systemic lupus erythematosus in a Phase Ib/II clinical trial has been approved by the U.S. Food and Drug Administration.
Source:Aug 19, 2026, 14:48 UTC
Yimufeng Biotech resubmitted its Hong Kong IPO application.